A big pharmaceutical company called on Morrison & Foerster partner Thomas Ciotti and associate Mika Mayer in April, eager to spend $10 billion on a biotech outfit. The drug maker needed due diligence on the target’s intellectual property portfolio. Two months of vetting uncovered serious problems with the biotech’s patents, and Ciotti and Mayer advised the client to drop the acquisition.

“They wanted to do the deal so badly, they hired another law firm to look at the portfolio,” Ciotti recalled. “But they must have gotten the same assessment, and the deal never went through.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]